Fetal RHD determination using Non-Invasive Prenatal Testing (NIPT) has long been the realm of research laboratories using home-made reagents, but is now entering routine laboratories as part of large prenatal screening programs. As a result, the demands on the testing procedures are changing to establish workflows that are robust, standardized and adapted to high-throughput screening. High sensitivity and specificity of the assay is critical, but it is also important to optimize the entire workflow including sample handling, data interpretation and results reporting.
Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis. M Neovius et al. BJOG. 2016 Jul;123(8):1337-46.